To investigate efficacy, pharmacodynamics, and safety of BC 007 in participants with long COVID

Phase 1

• Conditions: long Covid; MedDRA version: 25.1Level: LLTClassification code 10087832Term: COVID-19 reboundSystem Organ Class: 10021881 - Infections and infestations; Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]

• Registration Number: EUCTR2022-003452-14-DE
• Lead Sponsor: Berlin Cures GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-21
• Last Update Posted: 18 March 2024

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 114

Inclusion Criteria

1. The participant provides written informed consent prior to any clinical study-specific procedures.
2. The participant is a male or female, =18 years of age, at the time of signing the informed consent form.
3. All male and female participants of childbearing potential must be willing to use effective methods of contraception from the start of Screening until EOS (Day 90). Male participants must refrain from donating sperm during this period.
4. Acute phase of COVID-19 ended at least 3 months prior to dosing.
5. The participant has a confirmed negative SARS-CoV-2 test result (polymerase chain reaction [PCR] test) at screening.
6. The participant provides a documented positive SARS-CoV-2 test result (reverse transcriptase [RT]-PCR or rapid antigen test) at Screening. For participants with long COVID symptoms who cannot provide certified evidence, a positive antibody test for nucleocapsid protein IgG must demonstrate a history of SARS-CoV-2 infection; this test can be performed as part of the Screening procedure. The participant reports persistence or new onset of symptoms after a SARS- CoV-2 infection, with these symptoms lasting for at least 2 consecutive months (being persistent, recurrent, or of varying severity within that period) with no other explanation, as defined by WHO, and not being
7. Participant is screened positive for GPCR-AAB activity by Berlin Cures laboratory.
8. Participant has not been intubated or received ECMO support during their acute COVID-19 infection.
9. Participant screens positive for fatigue (FACIT-FS score <35) and presents with at least one additional symptom from the symptom score sheet (COA) which has persisted for more than 12 weeks.
10. Participant is not on any permanent medication(s) to treat chronic diseases that existed prior to COVID19 infection. Exceptions are clinically stable conditions, which do not affect the study assessments and may be allowed as judged by the Investigator after discussion with the medical monitor. Clinically unstable is defined as a diagnosis or condition requiring changes in disease management within 2 months prior to start of Screening and includes ongoing workup of an
undiagnosed illness that could lead to a new diagnosis or condition.
Concomitant treatment may be permitted if:
• A treatment (type and dose) remained unchanged within the 2 months
before the start of Screening.
• No change in treatment is expected or required between Screening
visit and Day 30 of the study.
• A treatment does not affect any of the study assessments, in particular
by (e.g.,) causing fatigue or by impairing concentration ability.
As judged by the Investigator and after discussion with the medical monitor, possible allowed concomitant medications include but are not limited to:
• Antihypertensives (ß-blockers are NOT allowed)
• Lipid lowering agents.
• Antidiabetics (insulin is NOT allowed)
• Thyroid hormone replacement.
• Topical treatments.
• Low dose acetylsalicylic acid (up to 100 mg/day).
• Ivabradine
11. Participant reports that his/her activity level was not impaired prior to acute COVID-19 infection.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 100
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 14

Exclusion Criteria

1. Postural Orthostatic Tachycardia Syndrome existing prior to the initial SARS-CoV-2 infection leading to long COVID, as per medical history. History or evidence of any clinically significant cardiovascular disease.
2. Any history or presence of a major gastrointestinal, endocrinologic (e.g., insulin-dependent diabetes), cardiovascular, hematologic, hepatic, immunologic, metabolic (specifically gout), urologic, pulmonary (e.g., allergic or intrinsic asthma), neurologic, dermatologic, renal and/or other major disease, as judged by the Investigator. Other clinically stable conditions, which do not affect the study assessments may be allowed as judged by the Investigator after discussion with the medical monitor.
Possible allowed diseases are (if stable and well-controlled) include but are not limited to:
• Respiratory disorders (e.g., asthma-like) that first appear with longCOVID.
• Mild hypertension (<160 mmHg systolic, <100 mmHg diastolic)without known organ or vessel damage.
• Non-insulin-dependent diabetes mellitus without known organ orvessel damage.
• Glaucoma.
• Hypercholesterolemia/hypertriglyceridemia.
• Hypothyreosis.
3. Participants with history of major active or chronic unstable psychiatric illness (e.g., but not limited to, depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year.
4. Any history of any other chronic neurological, or psychological disease such as, but not limited to, chronic fatigue syndrome, fibromyalgia,systemic lupus erythematosus, Sjogren's syndrome. Any history or presence of relevant allergic reactions (e.g., requiring hospital stay, intravenous [i.v.] treatment or treatment with systemic steroids). A participant will not be included if it is likely that seasonal allergic symptoms will require any kind of systemic treatment until Day 30 of the study.
5. Participant has a history of hypersensitivity to the study intervention or any of the excipients or to medicinal products with similar chemical structures.
6. Participant has any other condition, which in the opinion of the Investigator precludes the participant’s participation in the clinical study.
7. Participant shows clinically significant abnormalities in clinical chemistry or haematology at screening, as judged by the Investigator; additionally, a participant will not be included if the laboratory shows at least one of the following results at Screening:
• Thrombocytes <100.000/µL.
• Hb • Alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT) >2× upper limit of normal (ULN).
• International normalized ratio (INR) >1.2.
8. Female participant is pregnant and/or breast feeding.
9. Participant participated in a previous clinical study (within 30 days or 5 half-lives of the investigational drug, whichever is longer prior to start of Screening) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s), or participant previously participated in this study and received study intervention.
10. Participant is an employee of the Sponsor, or contract research organization (CRO) conducting the study.
11. Participant has a close affiliation with the investigational site, e.g., a close relative of the Investigator, dependent person (e.g., employee or student of the investigational site).
12. Participant with an estimated glomerular filtration rate <60 mL/min/1,73 m².
13. Participan

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified